Psyence Biomedical’s operating cash use falls to $395K
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Psyence Biomedical Ltd. (PBM) reported a net loss of $1,937,058 for the six months ended September 30, 2026, versus $1,992,732 in the six months ended September 30, 2025. Operating cash used fell to $394,565 from $2,029,147; PBM attributed reduced outflows to $897,751 in prepaid amounts realized and $424,695 in insurance recoveries. Cash and cash equivalents, including restricted cash, were $21,140,337 at September 30, 2026, versus $7,491,954 at March 31, 2026. Research and development expense was $890,254, chiefly for its Australian Phase IIb study, where multiple patients had been enrolled and dosed.
On October 1, 2026, PBM issued 1,497,500 common shares at a deemed $6.00 per share for 3,473 PsyLabs shares; on October 16, 2026, it subscribed for 1,014 more at $2,564 per share for $2,599,896, bringing its PsyLabs holding to 11,565 shares, approximately 43.37%. Net ELOC proceeds were $16,780,447 for the six months. The ELOC permits sales of up to $100 million in shares through December 31, 2027, subject to agreement conditions, with $61,836,722 available as of November 19, 2026. Psyence Australia received an AUD $1,034,681 ($710,363) research-and-development rebate on November 10, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointOperating cash used fell to $394,565 from $2,029,147.
Negative
- None.
Filing Explained
After the completed October share swap and subsequent issuances, Psyence Biomedical reported
Key Figures
Key Terms
equity line of credit financial
equity method financial
Phase IIb Study medical
cGMP ibogaine HCl technical
restricted stock units financial
revaluation model financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was PBM’s net loss for the six months ended September 30, 2026?
How much cash did PBM have at September 30, 2026?
How many patients is PBM’s Phase IIb study designed to include?
What are PBM’s terms with PsyLabs for U.S. ibogaine?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number:
(Translation of registrant’s name into English)
121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F ☐ Form 40-F
EXPLANATORY NOTE
Psyence Biomedical Ltd. (the “Company”) is filing this Form 6-K to file its unaudited condensed consolidated interim financial statements for the three and six months ended September 30, 2026 and 2025 (the “Interim Financial Statements”), attached hereto as Exhibit 99.1, along with its corresponding Management Discussion and Analysis, attached hereto as Exhibit 99.2.
1
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Unaudited Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended September 30, 2026 and 2025. | |
| 99.2 | Management Discussion and Analysis for the Unaudited Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended September 30, 2026 and 2025. | |
| 101.INS | Inline XBRL Instance Document. | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: November 19, 2026
| Psyence Biomedical Ltd. | ||
| By: | /s/ Jody Aufrichtig | |
| Name: | Jody Aufrichtig | |
| Title: | Chief Executive Officer and Director | |
3
Exhibit 99.1

Psyence Biomedical Ltd.
Unaudited Condensed Consolidated Interim Financial Statements
For the three and six months ended September 30, 2026 and 2025
Expressed in United States Dollars
(USD $)
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
Condensed Consolidated Interim Statements of Financial Position
As at September 30, 2026 and March 31, 2026
| USD $ | Note | As at (Unaudited) |
As at March 31, 2026 (Audited) |
|||||||||
| ASSETS | ||||||||||||
| Current assets | ||||||||||||
| Cash and cash equivalents | 5 | |||||||||||
| Restricted cash | 5 | |||||||||||
| Other receivables | ||||||||||||
| Loan receivable | 10 | - | ||||||||||
| Prepaids | ||||||||||||
| Total current assets | ||||||||||||
| Non-current assets | ||||||||||||
| Digital assets | 8 | |||||||||||
| Equipment | 6 | |||||||||||
| Investment in Associate | 13 | |||||||||||
| TOTAL ASSETS | ||||||||||||
| LIABILITIES | ||||||||||||
| Current liabilities | ||||||||||||
| Accounts payable and accrued liabilities | 7 | |||||||||||
| Derivative warrant liabilities | 9 | |||||||||||
| TOTAL LIABILITIES | ||||||||||||
| SHAREHOLDERS EQUITY | ||||||||||||
| Share Capital | 12 | |||||||||||
| Accumulated Deficit | ( | ) | ( | ) | ||||||||
| Warrant Reserve | ||||||||||||
| Options Reserve | 12 | |||||||||||
| Reserves | ||||||||||||
| TOTAL SHAREHOLDERS EQUITY | ||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | ||||||||||||
Approved on behalf of Board of Directors
| “Jody Aufrichtig” | “Warwick Corden-Lloyd” | |
| Chief Executive Officer and Director | Chief Financial Officer and Director |
The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

2
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss
For three and six months ended September 30, 2026 and 2025
| USD $ | Note | Three months ending September 30, 2026 |
Three months ending September 30, 2025 |
Six months ending September 30, 2026 |
Six months ending September 30, 2025 |
|||||||||||||||
| Expenses | ||||||||||||||||||||
| Sales and marketing | ||||||||||||||||||||
| Research and development | ||||||||||||||||||||
| General and administrative | 16 | |||||||||||||||||||
| Professional and consulting fees | 16 | |||||||||||||||||||
| Loss before other items | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
| Other items | ||||||||||||||||||||
| Depreciation | 6 | ( | ) | ( | ) | ( | ) | ( | ) | |||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
| Interest income | ||||||||||||||||||||
| Other income | 18 | - | ||||||||||||||||||
| Foreign exchange (loss)/gain | ( | ) | ( | ) | ( | ) | ||||||||||||||
| Fair value gain/(loss) on warrant liability | 9 | ( | ) | ( | ) | ( | ) | |||||||||||||
| Fair value gain on investment in Psyence Labs Ltd | 13 | - | - | |||||||||||||||||
| Fair value gain on digital assets | 8 | - | - | |||||||||||||||||
| Share of losses from Associate | 13 | ( | ) | - | ( | ) | - | |||||||||||||
| NET LOSS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
| Other comprehensive income/(loss) | ||||||||||||||||||||
| Foreign exchange (loss)/gain on translation | ( | ) | ( | ) | ||||||||||||||||
| TOTAL COMPREHENSIVE LOSS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
| Profit/(Loss) per share – basic & diluted | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
| Weighted average number of outstanding shares – basic & diluted | ||||||||||||||||||||
The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

3
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
Condensed Consolidated Interim Statements of Changes in Shareholder Equity
For the six months ended September 30, 2026 and 2025
| USD $ | Note | Number of shares |
Share capital | Warrant reserve |
Options Reserve |
Reserves | Accumulated Deficit |
Total shareholders’ equity |
||||||||||||||||||||||||
| Opening balance as at April 1, 2025 | - | ( | ) | |||||||||||||||||||||||||||||
| Issuance of shares to third party advisors | 12 | - | - | - | - | |||||||||||||||||||||||||||
| Issuance of shares for ELOC, net of issuance costs | 11/12 | - | - | - | - | |||||||||||||||||||||||||||
| Share based compensation | 16 | - | - | - | - | - | ||||||||||||||||||||||||||
| Exercise of RSU’s | 12 | - | ( | ) | - | - | - | |||||||||||||||||||||||||
| Net loss for the period | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||
| Other comprehensive loss | - | - | - | - | ( | ) | - | ( | ) | |||||||||||||||||||||||
| Balance, September 30, 2025 | ( | ) | ||||||||||||||||||||||||||||||
| Opening balance as at April 1, 2026 | ( | ) | ||||||||||||||||||||||||||||||
| Issuance of shares for ELOC, net of issuance costs | 11/12 | - | - | - | - | |||||||||||||||||||||||||||
| Share based compensation | 16 | - | - | - | - | - | ||||||||||||||||||||||||||
| Exercise of RSU’s | 12 | - | ( | ) | - | - | - | |||||||||||||||||||||||||
| Net loss for the period | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||
| Other comprehensive income | - | - | - | - | - | |||||||||||||||||||||||||||
| Balance, September 30, 2026 | ( | ) | ||||||||||||||||||||||||||||||
The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

4
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
Condensed Consolidated Interim Statements of Cash Flows
For the six months ended September 30, 2026 and September 30, 2025
| Note | Six months ending September 30, 2026 |
Six months ending September 30, 2025 |
||||||||||
| Net (loss)/ income | ( | ) | ( | ) | ||||||||
| Non-cash adjustment: | ||||||||||||
| Fair value loss on derivative warrant | 9 | |||||||||||
| Fair value gain on investment in Psyence Labs Ltd | 13 | - | ( | ) | ||||||||
| Fair value gain on digital assets | 8 | ( | ) | - | ||||||||
| Share of losses from Associate | 13 | - | ||||||||||
| Third party advisors share issuance | 12 | - | ||||||||||
| Share based compensation | 16 | |||||||||||
| Depreciation | 6 | |||||||||||
| Foreign exchange | ( | ) | ||||||||||
| Changes in working capital: | ||||||||||||
| Other receivables | ( | ) | ||||||||||
| Loan receivable | 10 | - | ||||||||||
| Prepaids | ( | ) | ||||||||||
| Accounts payable and accrued liabilities | 7 | |||||||||||
| Cash used in operating activities | ( | ) | ( | ) | ||||||||
| Additions to equipment | 6 | ( | ) | ( | ) | |||||||
| Investment in Psyence Labs | 13 | ( | ) | ( | ) | |||||||
| Increase in restricted cash | 5 | ( | ) | ( | ) | |||||||
| Repayment of loan receivable | 10 | - | ||||||||||
| Cash used for investing activities | ( | ) | ( | ) | ||||||||
| Net proceeds received from ELOC | 11 | |||||||||||
| Cash provided from financing activities | ||||||||||||
| Change in cash and cash equivalents | ||||||||||||
| Cash and cash equivalents, beginning of period | ||||||||||||
| Cash and cash equivalents, end of period | ||||||||||||
The accompanying notes are an integral part of the Condensed Consolidated Interim Financial Statements

5
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
Notes to the Condensed Consolidated Interim Financial Statements
1. Nature of operations
Psyence Biomedical Ltd. (the “Company” or “PBM”), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin and ibogaine-based neuroplastogen medicines. The Company is working towards developing psychedelic therapeutics to treat mental health disorders. The Company is currently conducting research through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with a cancer diagnosis in a palliative care context (the “Clinical Trials”).
The Company’s registered office is at 121 Richmond Street West, PH Suite 1300, Toronto, Ontario M5H 2K1.
On November 26, 2024, the Company consolidated its common shares and warrants on the basis of 75:1.
On May 5, 2025, the Company consolidated its common shares and warrants on the basis of 7.97:1.
On February 2, 2026, the Company consolidated its common shares and warrants on the basis of 6.25:1.
All prior share capital information, including comparative figures, has been presented based on these ratios.
2. Basis of presentation
Statement of compliance
These Condensed Consolidated Interim Financial Statements have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (“IASB”). Accordingly, certain disclosures included in annual consolidated financial statements prepared in accordance with IFRS® Accounting Standards as issued by the International Accounting Standards Board (“IFRS”) have been condensed or omitted and these Unaudited Condensed Consolidated Interim Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements for the year ended March 31, 2026 and March 31, 2025. These Unaudited Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent annual consolidated financial statements.
The Condensed Consolidated Interim Financial Statements were authorized for issue on November 19, 2026 by the directors of the Company.
Basis of consolidation
These Condensed Consolidated Interim Financial Statements incorporate the accounts of PBM and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.
Control exists when an investor is exposed, or has the rights, to variable returns from the involvement with the investee and has the ability to affect those returns through its power over the investee.
The subsidiaries of PBM as at September 30, 2026 for the purpose of these Condensed Consolidated Interim Financial Statements are as follows:
| Name of entity | Place of incorporation | % ownership | Accounting method | |||||
| Psyence Australia Pty Ltd. | % | |||||||
| Psyence Biomed II Corp. | % | |||||||
| Newcourt Acquisition Corp. | % | |||||||
| Texas Ibogaine Research Corporation | % | |||||||

6
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
Inter-company balances and transactions are eliminated upon consolidation.
Texas Ibogaine Research Corporation (“TIRC”) was incorporated in the State of Texas on September 8, 2026 as a wholly owned subsidiary of Psyence Biomed II Corp.
Functional and presentation currency
These Condensed Consolidated Interim Financial Statements are presented in United States Dollars (“USD $”), which is also PBM’s functional currency. The USD $ represents the currency of the Company’s funding and is the currency of the primary economic environment in which the Company operates in, except for the Company’s Australian subsidiary which has an Australian Dollar functional currency.
3. Material accounting policies
These Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent Annual audited Consolidated Financial Statements.
Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 9 and IFRS 7) became effective for annual reporting periods beginning on or after January 1, 2026 and were adopted by the Company on April 1, 2026. The adoption of these amendments did not have a material impact on these Condensed Consolidated Interim Financial Statements.
Accounting Standards Issued But Not Yet Effective
A number of new standards, and amendments to standards and interpretations, are not yet effective for the period ended September 30, 2026, and have not been early adopted in preparing these consolidated financial statements.
IFRS 18 Presentation and Disclosure in Financial Statements
In April 2024, the IASB issued IFRS 18 – Presentation and Disclosure in Financial Statements which will replace IAS 1, Presentation of Financial Statements. The key new concepts introduced in IFRS 18 relate to the structure of the statement of earnings (loss), required disclosures in the financial statements for certain earnings or loss performance measures that are reported outside an entity’s financial statements and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general. IFRS 18 will apply for reporting periods beginning on or after January 1, 2027, and also applies to comparative information. The Company is still in the process of assessing the impact of this standard on its consolidated financial statements.
Other accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are not expected to have a significant impact on the Company’s consolidated financial statements.
4. Critical accounting estimates and judgements
These Condensed Consolidated Interim Financial Statements follow the same accounting policies, estimates, and methods of application as our most recent Annual audited Consolidated Financial Statements .

7
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
5. Cash, restricted cash and cash equivalents
Cash and cash equivalents include the following amounts:
| September 30, 2026 | March 31, 2026 | |||||||
| Unrestricted cash held with chartered banks | ||||||||
| Restricted cash | ||||||||
| Total | ||||||||
| ● | unrestricted cash and cash equivalents are held with chartered banks and an investment dealer, and include guaranteed investment certificates and term deposits; and |
| ● | the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $ |
6. Equipment
| Computer equipment | ||||
| Cost | ||||
| Opening balance, April 1, 2025 | ||||
| Additions | ||||
| At September 30, 2025 | ||||
| At March 31, 2026 | ||||
| Additions | ||||
| At September 30, 2026 | ||||
| Accumulated Depreciation | ||||
| Opening balance, April 1, 2025 | ( | ) | ||
| Charge for the period | ( | ) | ||
| At September 30, 2025 | ( | ) | ||
| At March 31, 2026 | ( | ) | ||
| Charge for the period | ( | ) | ||
| At September 30, 2026 | ( | ) | ||
| Carrying Value | ||||
| At March 31, 2026 | ||||
| At September 30, 2026 | ||||
7. Accounts payable and accrued liabilities
Accounts payable and accrued liabilities include the following amounts:
| September 30, 2026 | March 31, 2026 | |||||||
| Trade payables | ||||||||
| Accrued liabilities | ||||||||
| Provisions | ||||||||
| Total | ||||||||

8
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
8. Digital assets
During the year ended March 31, 2026, the Company deposited $
The following table summarizes the Company’s digital asset holdings as at September 30, 2026 and March 31, 2026:
Asset | Symbol | Quantity | Fair Value per Unit at September 30, 2026 | Fair value September 30, 2026 | Fair value March 31, 2026 | Revaluation Increase | ||||||||||||||||
| Bitcoin | BTC | $ | $ | $ | $ | |||||||||||||||||
| Ethereum | ETH | $ | $ | $ | $ | |||||||||||||||||
| Solana | SOL | $ | $ | $ | $ | |||||||||||||||||
| Tether | USDT | $ | $ | $ | - | |||||||||||||||||
| USD Coin | USDC | $ | $ | $ | - | |||||||||||||||||
| Cash (USD) | $ | $ | $ | - | ||||||||||||||||||
| Total | $ | $ | $ | |||||||||||||||||||
During the six months ended September 30, 2026, a revaluation gain of $
9. Derivative warrant liabilities
The Company has two classes of warrant liabilities outstanding: Public Warrants and Private Warrants. As of September 30, 2026 and March 31, 2026, there were
Public Warrants: The fair value of the Public Warrants is determined based on the observable market price, as they continue to be traded on the Nasdaq under the symbol “PBMWW.” Changes in fair value during the periods ended September 30, 2026 and September 30, 2025, have been recognized in the condensed consolidated interim statements of net loss and comprehensive loss.
Private Warrants:
Warrant Inputs at September 30, 2026 | Warrant Inputs at March 31, | |||||||
| Share price | $ | $ | ||||||
| Expected dividend yield | Nil | Nil | ||||||
| Exercise price | $ | $ | ||||||
| Risk-free interest rate | % | % | ||||||
| Expected life | ||||||||
| Expected volatility | % | % | ||||||
| Expiry date | ||||||||
At September 30, 2026 the fair value of the Public and Private Warrants was $

9
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
The expected volatility was based on implied volatility of the Public Warrants.
As at September 30, 2026, the derivative warrant liability was reconciled as follows:
Derivative warrant liability – Public and Private Warrants | ||||||||
| Number | Amount ($) | |||||||
| Opening balance April 1, 2025 | ||||||||
| Fair value loss | - | |||||||
| Balance as at September 30, 2025 | ||||||||
| Opening balance April 1, 2026 | ||||||||
| Fair value loss | - | |||||||
| Balance as at September 30, 2026 | ||||||||
Warrant transactions and the number of warrants outstanding are summarized as follows:
| Public Warrants | Private Warrants | |||||||||||||||
| Number of Warrants | Weighted Average Exercise Price | Number of Warrants | Weighted Average Exercise Price | |||||||||||||
| Balance, April 1, 2025 | $ | $ | ||||||||||||||
| Balance, September 30, 2025 and March 31, 2026 | $ | $ | ||||||||||||||
| Balance, September 30, 2026 | $ | $ | ||||||||||||||
The following warrants were outstanding and exercisable at September 30, 2026:
| Issue Date | Expiry Date | Exercise Price | Number of Warrants Outstanding | Number of Warrants Exercisable | ||||||||||
| January 25, 2024 | $ | |||||||||||||
10. Loan receivable
On February 9, 2026, the Company advanced a loan of $
On May 19, 2026, the Loan was repaid in full together with accrued interest of $

10
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
11. ELOC
On August 28, 2024, the Company entered into a $
During the six months ended September 30, 2026 the Company issued
12. Share capital
a) Authorized
The Company is authorized to issue an unlimited number of Common Shares, each without par value.
b) Issued and outstanding
On November 26, 2024, the Company consolidated its common shares on the basis of
On May 5, 2025, the Company consolidated its common shares and warrants on the basis of
On February 2, 2026, the Company consolidated its common shares and warrants on the basis of
All common shares, warrants and value per share amounts have been updated to reflect the share consolidations.
As at September 30, 2026, there were
| Common shares | Note | 2026 | 2025 | |||||||||||||||||
| Number | Amount ($) | Number | Amount ($) | |||||||||||||||||
| Opening balance April 1 | ||||||||||||||||||||
| Shares issued for ELOC | 11 | |||||||||||||||||||
| Shares issued to third party advisors | - | - | ||||||||||||||||||
| Shares issued on RSU exercise | ||||||||||||||||||||
| Share issuance costs | 11 | - | ( | ) | - | ( | ) | |||||||||||||
| Balance as at September 30 | ||||||||||||||||||||
Common shares
Issuance of shares to third party advisors
No common shares were issued to third party advisors during the six months ended September 30, 2026. In May 2025, the Company issued

11
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
c) Warrant Reserve
As at September 30, 2026, there were
The following warrants were outstanding and exercisable at September 30, 2026:
| Issue Date | Expiry Date | Exercise Price | Number of Warrants Outstanding | Number of Warrants Exercisable | ||||||||||
| December 24, 2024 | $ | |||||||||||||
| December 24, 2024 | $ | |||||||||||||
| December 24, 2024 | $ | |||||||||||||
d) Restricted Stock Units (RSUs)
| RSUs | 2026 | 2025 | ||||||
| Number | ||||||||
| Opening balance April 1 | - | |||||||
| RSU’s granted | ||||||||
| Exercised | ( | ) | ( | ) | ||||
| Cancelled | ( | ) | - | |||||
| Balance as at September 30, | ||||||||
On June 1, 2026, the Company issued
| ● |
| ● |
| ● |
The fair value of the RSUs was determined to be $
During the six months ended September 30, 2026,
13. Investment in Associate – Psyence Labs Ltd.
Psyence Labs Ltd. (“PsyLabs”) is a private company headquartered in the British Virgin Islands focused on the production of psychedelic active pharmaceutical ingredients and extracts. On February 25, 2026, the Company’s ownership interest in PsyLabs increased from
During August 2026, the Company acquired

12
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
On September 9, 2026, PsyLabs issued a pre-emption notice and backstop subscription commitment to the Company in respect of a new issue of up to
As at September 30, 2026, the Company held
The carrying amount of the investment in associate is reconciled as follows:
| Investment in Associate | ||||
| Carrying amount at March 31, 2026 | ||||
| Shares acquired from existing shareholders | ||||
| Subscription for new shares | ||||
| Share of associate net loss | ( | ) | ||
| Carrying amount at September 30, 2026 | ||||
During the three and six months ended September 30, 2026, the Company recognized its share of PsyLabs’ net loss of $
14. Capital management
The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern to pursue the development of natural health business, to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.
The Company manages its capital structure and adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust the amount of cash and cash equivalents on hand.
To facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.
Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company’s approach to capital management during the period.

13
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
15. Transactions with related parties
All related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. The Company incurred the following transactions with related parties during the periods ended September 30, 2026 and September 30, 2025:
Compensation to key management personnel
Key management personnel are those people who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly.
| Key Management Personnel | September 30, 2026 | September 30, 2025 | ||||||
| Short term benefits | ||||||||
| Share based compensation | ||||||||
| Total | ||||||||
Short term benefits consist of consulting fees, director’s fees, payroll and other benefits paid to key management personnel. This is included in the professional and consulting fees and general and administrative line items in the condensed consolidated interim statements of net loss and comprehensive loss.
Share-based compensation relates to RSUs granted to key management personnel.
During the six months ended September 30, 2026, the Company acquired
On September 25, 2026, TIRC and Psyence Labs Ltd. entered into a binding term sheet under which PsyLabs will grant TIRC an exclusive licence in the United States to PsyLabs’ know-how and related intellectual property for its cGMP ibogaine HCl, appoint TIRC as its exclusive supplier and wholesale distributor of the product in the United States, and receive development milestone payments totaling up to approximately US$
16. Share based compensation
During the period ended September 30, 2026, $

14
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
17. Financial instruments and financial risk management
a) Financial instrument classification and fair value measurement
Financial instruments that are recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.
The fair value of hierarchy has the following levels:
| ● | Level 1 – quoted prices in active markets for identical financial instruments. |
| ● | Level 2 – quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in the markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. |
| ● | Level 3 – valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
The table below presents the carrying value of the Company’s financial instruments:
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Digital assets | - | - | ||||||||||||||
| Derivative warrant liabilities – public warrants | - | - | ||||||||||||||
| Balance, September 30, 2026 | - | - | ||||||||||||||
| Digital assets | - | - | ||||||||||||||
| Derivative warrant liabilities – public warrants | - | - | ||||||||||||||
| Balance, March 31, 2026 | - | - | ||||||||||||||
There were no transfers in and out of level 3 during the period.
b) Risk management
In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company’s Board of Directors has overall responsibility for the establishment and oversight of the Company’s risk management framework.
Credit risk
Credit risk arises from cash, restricted cash and cash equivalents held with banks and investment dealers. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions.

15
PSYENCE BIOMEDICAL LTD.
Condensed Consolidated Interim Financial Statements (unaudited)
Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.
The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company’s main source of funding has been through equity investments and from government rebates in respect of research and development expenditure. The Company’s access to financing is uncertain. There can be no assurance of continued access to significant equity or debt funding.
The following table set forth the maturity of the contractual obligations as at September 30, 2026 and after
| Carrying Amount | Contractual Cash Flows | Less than 1 year | Between 1 and 3 years | |||||||||||||
| Accounts payable & accrued liabilities | - | |||||||||||||||
| Total contractual obligations | - | |||||||||||||||
Interest rate risk
Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s cash equivalents include fixed-rate guaranteed investment certificates and term deposits, and variable-rate deposit accounts. Assuming balances at September 30, 2026 are maintained and fixed-rate deposits are reinvested on maturity, a
Foreign exchange risk
Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.
As at September 30, 2026, a
18. Other income
Other income for the six months ended September 30, 2026 of $
19. Subsequent Events
Subsequent to period end, the Company received gross proceeds of $
On October 12, 2026, directors, consultants and employees of the Company exercised
On October 1, 2026, the Company completed a share-for-share swap with PsyLabs pursuant to the Share-for-Share Swap and Nomination Agreement dated September 21, 2026. The Company issued
On October 16, 2026, the Company completed the second part of the PsyLabs equity raise, subscribing for a further
On November 10, 2026, Psyence Australia Pty Ltd received a research and development tax incentive rebate of AUD $

16
Exhibit 99.2

Psyence Biomedical Ltd.
Management Discussion and Analysis (MD&A)
For the three and six months ended September 30, 2026 and 2025
Expressed in United States Dollars
(USD $)
Psyence Biomedical Ltd.
Management Discussion and Analysis
Operating and Financial Review for the three and six-month periods ended September 30, 2026 and 2025
The following discussion of the results of our operations and our financial condition should be read in conjunction with the unaudited condensed consolidated financial statements included as Exhibit 99.1 to this report. This discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. Actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those set forth in “Item 3. Key Information–D. Risk Factors” set forth in our Annual Report on Form 20-F for the year ended March 31, 2026 filed with the SEC on June 22, 2026.
This MD&A is dated November 19, 2026. Unless otherwise stated, all amounts are expressed in US dollars and are presented in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board, including IAS 34 Interim Financial Reporting. All share and per share amounts reflect the share consolidations completed on November 26, 2024 (75:1), May 5, 2025 (7.97:1) and February 2, 2026 (6.25:1), including for comparative periods.
Business overview
Psyence Biomedical Ltd. (NASDAQ:PBM) (the “Company” or “PBM”), is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in Neuroplastogens-based therapeutics, the manufacture of pharmaceutical-grade drug candidates and conducting clinical trials. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived Neuroplastogens treatments across a range of mental health disorders
We strive to set the global standard for excellence and consistency in drug development using nature-based psilocybin and ibogaine products. PBM’s priority is developing pharmaceutical grade psilocybin and ibogaine to help heal psychological trauma and the diagnosable disorders that can result therefrom, including adjustment disorder (“AjD”), alcohol use disorder (“AUD”), other substance use disorders, anxiety, depression, post-traumatic stress disorder (“PTSD”), and grief and bereavement, especially in the context of palliative care. Our focus includes therapeutic protocols for medical and scientific research including observational studies.
Our lead product candidate is NPX-5, a capsule containing 25mg naturally sourced psilocybin and which is being used in our Phase IIb double-blind, randomized, placebo (1mg low dose) controlled clinical trial to assess the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of AjD due to a cancer diagnosis (the “Phase IIb Study”).
We have contracted Southern Star Research, a contract research organisation (“CRO”) in Australia that specializes in the study of psychedelics, to conduct the Phase IIb Study. Outsourcing the Phase IIb Study to a CRO assists the Company in operating in a more capital efficient manner without the overhead of handling in-house. The study has received approval from the Australian Human Research Ethics Committees (HREC), numerous sites are currently active, and multiple patients have been dosed.
On September 8, 2026, the Company incorporated Texas Ibogaine Research Corporation (“TIRC”), a wholly owned subsidiary of Psyence Biomed II Corp., to advance the Company’s planned expansion into the treatment of opioid use disorder (“OUD”) using ibogaine in the United States. On September 25, 2026, TIRC and Psyence Labs Ltd. (“PsyLabs”) entered into a binding term sheet under which PsyLabs will grant TIRC an exclusive licence in the United States to PsyLabs’ know-how and related intellectual property for its cGMP ibogaine HCl, appoint TIRC as its exclusive supplier and wholesale distributor of the product in the United States, and receive development milestone payments totaling up to approximately US$1.3 million for the first drug candidate, an annual exclusivity fee commencing on the first anniversary of the first FDA approval and creditable against royalties, and a low single-digit percentage royalty on net sales of each drug candidate, together with a margin-sharing arrangement on any resale of product by TIRC.
The Company holds a significant interest in PsyLabs, a neuroplastogen active pharmaceutical ingredient development company, federally licensed in its operating jurisdiction to cultivate, extract and export psilocybin mushrooms and other neuroplastogen compounds, including psilocybin, psilocin, mescaline, ibogaine and dimethyltryptamine, to lawful medical and research markets. Psylabs is accounted for as an associate using the equity method. As at September 30, 2026 the Company held approximately 31.9% of PsyLabs, increasing to approximately 43.4% following the transactions completed in October 2026 described under “Subsequent events”.

2
Psyence Biomedical Ltd.
Management Discussion and Analysis
Operating results
Our key financial results for the three and six months ended September 30, 2026 and 2025 are summarized below:
| USD $ | Three months ended Sep 30, 2026 | Three months ended Sep 30, 2025 | Six months ended Sep 30, 2026 | Six months ended Sep 30, 2025 | ||||||||||||
| Sales and marketing | (105,506 | ) | (48,670 | ) | (119,646 | ) | (154,976 | ) | ||||||||
| Research and development | (527,967 | ) | (357,444 | ) | (890,254 | ) | (672,364 | ) | ||||||||
| General and administrative | (173,282 | ) | (217,225 | ) | (320,000 | ) | (367,070 | ) | ||||||||
| Professional and consulting fees | (782,312 | ) | (881,638 | ) | (1,151,393 | ) | (1,223,637 | ) | ||||||||
| Loss before other items | (1,589,067 | ) | (1,504,977 | ) | (2,481,293 | ) | (2,418,047 | ) | ||||||||
| Other income | 424,695 | - | 424,695 | 2,533 | ||||||||||||
| Interest income | 224,287 | 72,815 | 362,187 | 103,341 | ||||||||||||
| Fair value gain/(loss) on warrant liability | 39,072 | (58,016 | ) | (33,164 | ) | (98,272 | ) | |||||||||
| Fair value gain on digital assets | 165,868 | - | 105,888 | - | ||||||||||||
| Fair value gain on investment in Psyence Labs Ltd | - | 740,750 | - | 427,000 | ||||||||||||
| Share of losses from Associate | (171,261 | ) | - | (306,523 | ) | - | ||||||||||
| Depreciation, interest expense and foreign exchange | (6,499 | ) | (3,826 | ) | (8,848 | ) | (9,287 | ) | ||||||||
| Net loss for the period | (912,905 | ) | (753,254 | ) | (1,937,058 | ) | (1,992,732 | ) | ||||||||
| Loss per share – basic and diluted | (0.24 | ) | (3.18 | ) | (0.53 | ) | (11.76 | ) | ||||||||
| USD $ | September 30, 2026 | March 31, 2026 | ||||||
| Cash and cash equivalents, including restricted cash | 21,140,337 | 7,491,954 | ||||||
| Working capital | 20,837,679 | 8,487,385 | ||||||
| Investment in Associate | 10,740,433 | 8,060,928 | ||||||
| Total assets | 32,798,098 | 17,567,320 | ||||||
| Total liabilities | 718,502 | 623,190 | ||||||
| Total shareholders’ equity | 32,079,596 | 16,944,130 | ||||||
Comparative loss per share has been restated to reflect the 6.25:1 share consolidation completed on February 2, 2026.
Sales and marketing costs
For the six months ended September 30, 2026, we incurred sales and marketing costs of $119,646 (September 30, 2025: $154,976), consisting primarily of investor relations activities, travel, content creation, promotional materials and website-related costs. For the three months ended September 30, 2026, sales and marketing costs were $105,506 (September 30, 2025: $48,670).
The decrease for the six-month period reflects the Company’s reduced spending on investor relations and promotional activities. The increase for the three months ended September 30, 2026 reflects attendance at ARPA-H conferences in the United States and visits to a contract development and manufacturing organization (“CDMO”) in Texas in connection with the Company’s planned expansion into OUD using ibogaine through TIRC.
Research and development
For the six months ended September 30, 2026, we incurred research and development costs of $890,254 (September 30, 2025: $672,364), of which $878,347 related to the Phase IIb Study conducted in Australia, $6,952 to the Company’s ibogaine program through TIRC and $4,956 to other research activities. For the three months ended September 30, 2026, research and development costs were $527,967 (September 30, 2025: $357,444) which was all related to the Phase IIb Study conducted in Australia.
The increase reflects the continued progression of the Phase IIb Study under Southern Star Research, including patient recruitment and dosing, site management, monitoring and ongoing trial management across the activated trial sites. The research and development tax incentive rebate was received after the period end. The Company expects research and development expenditure to continue to increase as the Phase IIb Study progresses and as the ibogaine program is developed through TIRC.

3
Psyence Biomedical Ltd.
Management Discussion and Analysis
General and administration costs
For the six months ended September 30, 2026, we incurred general and administrative costs of $320,000 (September 30, 2025: $367,070), which consisted of filing and listing fees, bank fees, directors’ and officers’ insurance, salaries and wages and operational costs. For the three months ended September 30, 2026, general and administrative costs were $173,282 (September 30, 2025: $217,225).
The decrease reflects the Company’s continued focus on cost discipline across corporate overhead and the normalization of public company compliance costs.
Professional and consulting fees
For the six months ended September 30, 2026, professional and consulting fees totalled $1,151,393 (September 30, 2025: $1,223,637). For the three months ended September 30, 2026, professional and consulting fees were $782,312 (September 30, 2025: $881,638).
This consisted of $954,974 (September 30, 2025: $420,298) paid to consultants, directors and key management personnel for business strategy, financial and administrative services, including non-cash share-based compensation of $269,043 on restricted stock units (“RSUs”), legal fees of $104,481 (September 30, 2025: $734,977) and $91,938 (September 30, 2025: $68,362) for audit and accounting fees.
The decrease in legal fees reflects the legal costs incurred on a higher volume of corporate transactions in the prior period. The increase in consulting fees reflects share-based compensation on the RSUs granted on October 1, 2025 and June 1, 2026, performance-related payments to consultants and expanded advisory support for the Company’s corporate and strategic initiatives.
Other income, gains and losses
Other income of $424,695 for the six months ended September 30, 2026 (September 30, 2025: $2,533) comprises insurance recoveries received from the Company’s insurer in respect of legal fees incurred in connection with the shareholder dispute with KAOS Capital Ltd., which was settled in February 2026.
Interest income increased to $362,187 (September 30, 2025: $103,341), driven by higher cash balances available for investment in guaranteed investment certificates and term deposits.
The Company recognized a fair value loss of $33,164 (September 30, 2025: loss of $98,272) on its derivative warrant liabilities, reflecting the movement in the quoted price of the public warrants, and a revaluation gain of $105,888 (September 30, 2025: $nil) on its digital asset portfolio, reflecting higher cryptocurrency prices at September 30, 2026.
Investment in Psyence Labs Ltd.
PsyLabs has been accounted for as an associate using the equity method since February 25, 2026. For the three and six months ended September 30, 2026, the Company recognized its share of PsyLabs’ net loss of $171,261 and $306,523, respectively. In the comparative period the investment was measured at fair value through profit or loss, and an unrealized fair value gain of $427,000 was recognized for the six months ended September 30, 2025.
During the six months ended September 30, 2026, the Company invested a further $2,986,028 in cash in PsyLabs, comprising 242 shares acquired from existing PsyLabs shareholders at $2,422 per share for $586,124 and 936 new shares subscribed at $2,564 per share for $2,399,904 in the first part of PsyLabs’ $5.5 million equity raise. As at September 30, 2026, the Company held 7,078 PsyLabs shares, representing approximately 31.9% of PsyLabs’ issued and outstanding shares, and the carrying amount of the investment was $10,740,433 (March 31, 2026: $8,060,928).

4
Psyence Biomedical Ltd.
Management Discussion and Analysis
Update to Palliative Care Clinical Trial
The 87 - patient Phase IIb Study being conducted by the CRO, Southern Star Research, in Australia is the one that was discussed with the FDA at the pre-IND stage. The study has received ethics (HREC) approval, and multiple patients have been enrolled and dosed.
Liquidity and capital resources
Since incorporation, our operations have been financed primarily through equity, including investment by our shareholders, a private placement and an equity line of credit (“ELOC”), together with a convertible debt note and research and development tax incentive rebates from the Australian Government. Our main use for liquidity is funding scientific research, clinical studies, salaries and professional and consulting fees. Our ability to fund operations and to make planned cash flows are subject to prevailing economic conditions, regulatory and financial, business, and other factors, some of which are beyond our control.
As of September 30, 2026, we had cash and cash equivalents, including restricted cash, of $21,140,337 (March 31, 2026: $7,491,954) and working capital of $20,837,679 (March 31, 2026: $8,487,385). Cash and cash equivalents include guaranteed investment certificates and term deposits held with a chartered bank and an investment dealer.
For the six months ended September 30, 2026, cash used in operating activities was $394,565 (September 30, 2025: $2,029,147). Operating cash outflows were reduced by the realization of prepaid amounts of $897,751, including funds held in trust with attorneys at March 31, 2026, and by insurance recoveries of $424,695. Cash used in investing activities was $2,762,118 (September 30, 2025: $4,011,455), primarily comprising the $2,986,028 investment in PsyLabs, partly offset by the repayment of the $251,110 loan receivable. Cash provided by financing activities was $16,780,447 (September 30, 2025: $7,055,421), being the net proceeds from the issuance of 1,519,383 common shares under the ELOC.
The ELOC with White Lion Capital, LLC, as amended, allows the Company to sell up to $100 million of its common shares until December 31, 2027, subject to the conditions set out in the purchase agreement. As at the date of this MD&A, $61,836,722 remains available under the ELOC.
The Company’s material cash requirements as at September 30, 2026 comprise its commitments for the Phase IIb Study, the development of its ibogaine program, and its backstop subscription commitment to PsyLabs of up to $2,600,000, which was satisfied on October 16, 2026 with a payment of $2,599,896. The Company expects to fund these requirements with available cash and cash equivalents, and therefore, is subject to risks including, but not limited to, an inability to raise additional funds through the issuance of equity, debt instruments or similar means of financing to support the Company’s continued development, including operating requirements, and to meet its liabilities and commitments as they become due.
The Company has experienced cash outflows from operations since incorporation and by nature of its business, will require ongoing financing to continue its research and development operations. The Company’s ability to access both public and private capital is dependent upon, among other things, general and sectoral market conditions and the capital markets generally, market perceptions about the Company and its business operations, and the trading prices of the Company’s securities from time to time. There can be no assurance that additional funds can be raised upon terms acceptable to the Company, or at all, as funding for early-stage companies remain challenging generally.
The Company’s primary capital needs are funds to advance its research and development activities and for working capital purposes. These activities include staffing, pre-clinical studies, clinical trials, professional and consulting fees and general and administrative costs. There is no assurance that additional capital or other types of financing will be available if needed or that these financings will be on terms at least as favourable for the Company as those previously obtained, or at all.
Research and development, patents and licenses
Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and comprehensive loss as incurred.

5
Psyence Biomedical Ltd.
Management Discussion and Analysis
Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.
Critical Accounting Estimates
The preparation of financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results may differ from these estimates. The Company’s management reviews these estimates, judgments, and assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical accounting policies as these require a high level of subjectivity and judgement and could have a material impact on PBM’s financial statements.
Investment in associate
Management applied judgment in determining that the Company has significant influence over PsyLabs and accounts for its interest using the equity method. The Company’s share of PsyLabs’ results is based on PsyLabs’ management accounts for the period. At each reporting date management assesses whether there is objective evidence that the investment is impaired, which requires judgment regarding PsyLabs’ financial performance, funding and development progress.
Digital assets
Digital assets are accounted for as intangible assets using the revaluation model under IAS 38, with fair values determined by reference to quoted prices on active exchanges. Judgment is required in the classification of digital assets and in determining whether revaluation movements are recognized in profit or loss or other comprehensive income.
Share-based compensation
The fair value of RSUs is measured by reference to the market price of the Company’s common shares on the grant date, and the expense is recognized over the vesting period based on management’s estimate of the number of RSUs expected to vest.
Quantitative and Qualitative Disclosures About Financial Instruments and Financial Risk Management
In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management, as well as monitoring. Our Board has overall responsibility for the establishment and oversight of the Company’s risk management framework.
Credit risk
Credit risk arises from cash, restricted cash and cash equivalents held with banks and an investment dealer, and from digital assets held with a regulated digital asset custodian. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions. The Company also assesses the credit quality of counterparties, taking into account their financial position, past experience and other factors.

6
Psyence Biomedical Ltd.
Management Discussion and Analysis
Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.
The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. The Company’s access to financing is always uncertain and there can be no assurance of continued access to significant equity or debt funding on terms satisfactory to the Company, or at all.
Foreign exchange risk
Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.
The Company operates internationally and is exposed to foreign exchange risk from the Canadian Dollar and the Australian Dollar. Foreign exchange risk arises from transactions as well as recognized financial assets and liabilities denominated in foreign currencies.
A 10% adverse change in exchange rate would have resulted in a loss of $70,088 as of September 30, 2026.
Management mitigates the risk of adverse exchange rate movements by holding funds in US dollars.
Interest rate risk
Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s cash equivalents include fixed-rate guaranteed investment certificates and term deposits, and variable-rate deposit accounts. Assuming balances at September 30, 2026 are maintained and fixed-rate deposits are reinvested on maturity, a 1% change in interest rates would change interest income over the following twelve months by $99,522. The Company has no interest-bearing liabilities.
Digital asset price risk
The Company is exposed to price risk on its portfolio of digital assets. A 10% decrease in the prices of the portfolio of digital assets at September 30, 2026 would have decreased the carrying amount of digital assets, and increased net loss, by approximately $48,635.
Capital Management
The Company’s objectives when managing its capital are to safeguard its ability to continue as a going concern, to meet its capital expenditures for its continued operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, issue debt, or acquire or dispose of assets. The Company is not subject to externally imposed capital requirements.
Management reviews its capital management approach on an ongoing basis. The Company considers its shareholders’ equity balance as capital.
Off-Balance Sheet Arrangements
We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2026. We do not participate in transactions that create relationships with entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities or guaranteed any debt or commitments of other entities.
Contractual Obligations
We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities.
As at September 30, 2026, the Company’s contractual obligations comprised accounts payable and accrued liabilities of $469,862, all due within one year, and its backstop subscription commitment to PsyLabs of up to $2,600,000, which was satisfied on October 16, 2026.

7
Psyence Biomedical Ltd.
Management Discussion and Analysis
Transactions with related parties
Compensation to key management personnel for the six months ended September 30, 2026 was $662,185 (September 30, 2025: $492,342), comprising short-term benefits of $459,502 (September 30, 2025: $469,346) and share-based compensation of $202,683 (September 30, 2025: $22,996). During the period the Company also acquired 130 PsyLabs shares from certain existing PsyLabs shareholders that are related parties of the Company, at $2,422 per share. Refer to Note 15 of the unaudited condensed consolidated interim financial statements.
Outstanding share data
As at September 30, 2026, the Company had 3,816,548 common shares, 41,656 equity-classified warrants, 3,322 derivative warrants and 145,818 RSUs outstanding. As at the date of this MD&A, the Company had 5,318,218 common shares, 41,656 equity-classified warrants, 3,322 derivative warrants and 143,228 RSUs outstanding.
Subsequent events
On October 1, 2026, the Company completed a share-for-share swap with PsyLabs, issuing 1,497,500 common shares to PsyLabs at a deemed issue price of $6.00 per share in exchange for 3,473 new PsyLabs shares issued to Psyence Biomed II Corp. The fair value of the common shares issued, based on the closing share price of $5.48 on October 1, 2026, was $8,206,300.
On October 16, 2026, the Company subscribed for a further 1,014 PsyLabs shares at $2,564 per share for $2,599,896, completing its participation of approximately $5.0 million in PsyLabs’ $5.5 million equity raise. Following these transactions, the Company holds 11,565 PsyLabs shares, representing approximately 43.4% of PsyLabs’ issued and outstanding shares.
On November 10, 2026, Psyence Australia Pty Ltd received a research and development tax incentive rebate of AUD $1,034,681 ($710,363) from the Australian Taxation Office under the Australian Federal Government’s Research and Development Tax Incentive Program, in respect of eligible research and development expenditure incurred in Australia. In accordance with the Company’s accounting policy for government grants, the rebate will be recognized as other income in the period in which it was received.
Subsequent to period end, the Company received gross proceeds of $8,374 for the issuance of 1,580 common shares under the ELOC, and on October 12, 2026 directors, consultants and employees of the Company exercised 2,590 RSUs into common shares.

8